FDA Awards Orphan Drug Status to Immunocore for Uveal Melanoma Candidate

U.K.-based Immunocore has nabbed orphan drug status from the FDA for IMCgp100, a candidate for the treatment of uveal melanoma.

There are currently no effective treatments on the market for the disease, which affects the eye and makes up roughly 3 percent of all melanomas. The treatment is currently in Phase 2a clinical trials.